The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.
Jan Baptist Vermorken
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Frederic Peyrade
Consultant or Advisory Role - Merck KGaA
Honoraria - Merck KGaA
Juergen Krauss
No relevant relationships to disclose
Ricard Mesia
Consultant or Advisory Role - Merck
Research Funding - Merck
Eva Remenar
No relevant relationships to disclose
Thomas C. Gauler
Consultant or Advisory Role - Merck
Honoraria - Merck Serono
Ulrich Keilholz
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Jean-Pierre Delord
No relevant relationships to disclose
Philippe Schafhausen
Honoraria - Merck Serono
Jozsef Erfán
No relevant relationships to disclose
Tim H. Brummendorf
Honoraria - Merck KGaA
Lara Iglesias
No relevant relationships to disclose
Ullrich Bethe
Employment or Leadership Position - Merck KGaA
Guillaume de La Bourdonnaye
Employment or Leadership Position - Merck Serono
Paul M. Clement
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono